BeOne Medicines Ltd.
ONC
$308.63
-$5.04-1.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 17.72% | -6.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.72% | -6.00% | |||
| Cost of Revenue | 317.87% | -4.63% | |||
| Gross Profit | -34.28% | -6.23% | |||
| SG&A Expenses | 17.12% | -13.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.96% | -12.46% | |||
| Operating Income | 691.61% | 114.80% | |||
| Income Before Tax | 376.31% | 131.84% | |||
| Income Tax Expenses | -73.36% | -73.50% | |||
| Earnings from Continuing Operations | 7,326.77% | 100.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7,326.77% | 100.91% | |||
| EBIT | 691.61% | 114.80% | |||
| EBITDA | 175.55% | 228.51% | |||
| EPS Basic | 7,216.81% | 100.91% | |||
| Normalized Basic EPS | 341.43% | 135.53% | |||
| EPS Diluted | 6,742.11% | 100.87% | |||
| Normalized Diluted EPS | 341.60% | 134.18% | |||
| Average Basic Shares Outstanding | 1.30% | 0.63% | |||
| Average Diluted Shares Outstanding | 1.25% | 4.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||